TRex Bio raised $116.7 million in a U.S. IPO, pricing at the bottom of its range
FROM THE PUBLISHER
The clinical-stage biotech sold about 8.3 million shares at $14 each, the low end of its $14-to-$16 marketed range
Original reporting by Quartz. Some articles may require a subscription.